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Abstract
Virus host evasion genes are ready-made tools for gene manipulation and therapy. In this work we have assessed the
impact in vivo of the evasion gene A238L of the African Swine Fever Virus, a gene which inhibits transcription mediated by
both NF-kB and NFAT. The A238L gene has been selectively expressed in mouse T lymphocytes using tissue specific
promoter, enhancer and locus control region sequences for CD2. The resulting two independently derived transgenic mice
expressed the transgene and developed a metastasic, angiogenic and transplantable CD4+CD8+CD69– lymphoma. The
CD4+CD8+CD69– cells also grew vigorously in vitro. The absence of CD69 from the tumour cells suggests that they were
derived from T cells at a stage prior to positive selection. In contrast, transgenic mice similarly expressing a mutant A238L,
solely inhibiting transcription mediated by NF-kB, were indistinguishable from wild type mice. Expression of Rag1, Rag2,
TCRb-V8.2, CD25, FoxP3, Bcl3, Bcl2 l14, Myc, IL-2, NFAT1 and Itk, by purified CD4+CD8+CD69– thymocytes from A238L
transgenic mice was consistent with the phenotype. Similarly evaluated expression profiles of CD4+CD8+ CD69– thymocytes
from the mutant A238L transgenic mice were comparable to those of wild type mice. These features, together with the
demonstration of (mono-)oligoclonality, suggest a transgene-NFAT-dependent transformation yielding a lymphoma with a
phenotype reminiscent of some acute lymphoblastic lymphomas.
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Introduction
Viruses have evolved multiple strategies to manipulate and
evade host cell biology and immune responses [1–8]. Paradoxi-
cally, however, virus host evasion genes potentially provide ready-
made tools to explore and manipulate the regulation of these basic
cellular processes. We have therefore advanced this concept
through construction of a transgenic mouse with T cell restricted
expression of a virus inhibitor of transcription, the A238L gene of
African Swine Fever Virus (ASFV). One domain of A238L, with
homology to IkBa, interacts with p65 of the NF-kB family of
transcription factors, thereby inhibiting its activation [9,10].
Another domain interacts with calcineurin phosphatase (CanPase),
(now known as protein phosphatase 3C or PP3C), thus inhibiting
activation of NFAT transcription factors [11–13]. A mutant
A238L (mutA238L) no longer capable of interaction with
CanPase, but still inhibiting the activation of p65, has been
characterised [12]. A third function of A238L was more recently
described and results in inhibition of p65/RelA acetylation and
inhibition of protein kinase C-h-dependent-p300 transcriptional
activation [14–17]. The p300 and CBP proteins play a key role in
transcriptional regulation of a myriad of genes which do not bind
directly to the promoters of such genes, but are recruited through
interaction with several transcription factors, for example, NF-kB
and NFAT [18–20].
A number of mice lacking expression of NF-kB or NFAT have
been constructed in order to define the roles of these transcription
factors. Manipulation of such key intracellular signalling molecules
through transgenic expression of a viral host modification gene,
however, provides an alternative strategy to explore the role of
such proteins. As the transcription factors targeted by the A238L
transgene are expected to have pleiotropic effects in a variety of
cell types, expression of A238L as a conventional murine
transgene in vivo might be lethal, or altogether too complicated
to analyse. Therefore, expression of the A238L virus transgene was
restricted to T cells, as the development and function of these
lymphocytes is very well understood, thereby providing an
excellent system to explore the impact of the transgene.
The resulting T cell restricted A238L transgenic mice developed
transplantable, angiogenic thymic tumours, whose T cells were
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CD4+CD8+CD692 (mono-)oligoclonal lymphoblasts, with uncon-
trolled growth in the thymus and metastasis to both the secondary
lymphoid organs (spleen and lymph nodes) and to non-lymphoid
tissues, such as kidney, lung and liver. In contrast, the mutA238L
transgenic mice were indistinguishable from wild type mice,
suggesting that NFAT is essential for the neoplastic transformation
in the A238L, T cell restricted transgenic mice.
Results
Evaluation of the Number of Copies of the Transgene
The number of copies of the transgene incorporated in the
genome of the two A238L founders, as assessed by the Light
Cycler technology, was 10 and 30, and the transgene sequence was
identical to the published NCBI A238L sequence. The phenotypic
analysis presented was performed in two of the four founder mouse
lines.
The number of copies of the transgene incorporated in the
genome of the mutA238L founder mice, as assessed by the Light
Cycler technology, was estimated to vary between 10 and 20. The
phenotypic analysis presented was performed in two of the four
founder mouse lines.
Expression of the Transgenes
Expression of the transgenes, A238L and mutA238L, was
confirmed at the RNA level by RT-PCR, and at the protein level
by western blot and immunofluorescence using an antibody
specific for the HA immunotag. Expression of the A238L and
mutA238L transgene in purified splenic B cells was either negative
or low, in the latter case attributable to contamination of the
purified B cells (Figure 1A and 1B). In all the F1 and F2 mice from
both founders of each genotype that were analysed, expression of
the transgene was confirmed at both protein and RNA levels with
transgenic thymus, spleen, lymph nodes, in the organs where there
was infiltration of the transgenic cells, and also in the thymic cell
lines established from the A238L transgenic mice (Figure 1C).
Expression of the A238L and mutA238L transgenic proteins was
confirmed by immunostaining of transgenic thymus cryostat
sections (Figure 1E and 1F).
Clinical Symptoms and Phenotypic Analysis of A238L
Transgenic Mice
Both homo and heterozygous A238L transgenic mice developed
breathing difficulties, lost body fat and displayed a darker red tone
in their eyes, suggesting that they were not oxygenating properly.
The onset of these symptoms was variable, occurring between 2–
12 months of age. The sick A238L mice always had an enlarged
thymus, up to 15–20 times the size of a normal thymus (Figure 2A),
and also presented enlarged spleens and lymph nodes (Figures 2B
and 2C). There was a dramatic difference in the organisation of
the A238L transgenic thymus on the one hand (Figure 2E), and
the wild type (Figure 2D) or mutA238L transgenic thymuses on
the other (Figure 2F). Most of the cells in the A238L transgenic
mice were typical blasts with a prominent nucleolus, peri-nuclear
chromatin and with cytological features of lymphoblastic lympho-
ma cells. There was an increase in cells with dense apoptotic nuclei
in the transgenic thymus (Figure 2G). Importantly, the organisa-
tion of the mutA238L transgenic thymus was indistinguishable
from the control mice.
Figure 1. Expression of the A238L transgene confirmed by RT-PCR and by detection of the protein. A) B) RT-PCR for the A238L gene is
negative in transgenic splenic B cells after MACS purification (lane 1), and positive in total splenocytes (lane 2) and total thymocytes (lane 3). The
upper bands are the A238L PCR product, and the bottom bands are the tubulin controls. C) A similar RT-PCR analysis of two cell lines independently
established from the thymuses of two different A238L T cell transgenic mice (lanes 1 and 2), and of a tumour that developed as the result of
subcutaneous injection of thymic transgenic cells (lane 3). The upper bands are the A238L PCR product, and the bottom bands are the tubulin
controls. Immunofluorescent staining of control (D), A238L (E) and mutA238L (F) T cell restricted transgenic thymus cryostat sections using a rat
monoclonal antibody against the HA immunotag upstream the A238L transgene, followed by a goat anti-rat FITC (magnification 40X). The results are
representative of at least 5 mice per founder and per genotype.
doi:10.1371/journal.pone.0034140.g001
T Cell Lymphoma by Transgenic Expression of pA238L
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Increased proliferation in A238L transgenic thymuses was
confirmed by both cell cycle analysis of thymocyte cell suspensions
using propidium iodide and by incorporation of bromodeoxyur-
idine (BrdU) in vivo (data not shown). Again, cell cycle analysis and
incorporation of BrdU in vivo yielded similar results in the control
and mutA238L transgenic mice.
Detailed phenotypic analysis of the A238L transgenic thymus
lymphoblasts revealed the predominant population to be
CD4+CD8+CD692 (Figure 3A and 3B), but with lower levels of
expression of the ab-TCR than the normal control TCR positive
thymocytes (Figure 3D). The absence of CD69 expression
(Figure 3B) suggests that the A238L transgenic cells were derived
from T cells prior to positive selection.
The expression of CD25 and CD44 permits the definition of 4
distinct developmental stages in normal thymocytes prior to
positive selection. This analysis of the A238L transgenic animals,
clearly demonstrated a very different pattern of A238L transgenic
CD4+CD8+ double positive subpopulations, from that of the
control mice. In the latter, the CD4+CD8+ cells are almost
exclusively CD25–CD44– (Figure 3C, left), whereas in the A238L
transgenic animals the predominant cell (72%) corresponded to
CD25+CD44– cells and only 27% were CD252CD442 (Figure 3C,
right). In young A238L T cell restricted transgenic mice with
normal sized thymuses, the subpopulations identified by staining
with antibodies against CD4, CD8, CD25 and CD44, against
CD4, CD8 and CD69, and against CD3 and TCRab, were
always the same as that of the wild type control mice. Similarly,
staining with Thy-1, which allows evaluation of early haemato-
poietic differentiation, did not reveal differences in young A238L
T cell restricted Tg mice with normal sized thymuses. In contrast,
in the tumorigenic Tg mice, there were increased levels of
expression of Thy-1 (data not shown). As soon as the thymus was
significantly larger, this was accompanied by a clear increase in the
population of the CD4+CD8+CD692 phenotype lymphoblasts.
A similar analysis was performed in the mutA238L transgenic
mice and as can be seen the pattern of expression of CD4, CD8
and CD69 is the same as the control mice (Figure 3E), as well as
the expression of CD3 and ab-TCR (Figure 3F) and of CD25 and
CD44 (data not shown), which are comparable to the control
negative littermates. Similarly, these mice appeared normal, never
exhibiting the symptoms described for the A238L transgenic
animals.
Induction of Angiogenesis
The often appearance of blood in the A238L transgenic thymus
indicated an angiogenic stimulus, which was confirmed by the
presence of visible blood vessels containing red blood cells
(Figure 2E), absent in both the mutA238L transgenic and the
control mice, and the widespread distribution of anti-CD31
positive endothelial cells and of cells secreting vascular endothelial
growth factor (VEGF) (Figure 4, upper images). The actual cell
producing the VEGF has not been identified, but it is certainly not
an endothelial cell as it was clear by examination of thymus
sections counterstained with anti-CD31 (Figure 4, lower images).
No such phenotype was detectable in the mutA238L transgenic
mice which were always indistinguishable from the control mice
(Figure 4, right images).
Figure 2. Enlargement and loss of organization of lymphoid organs in A238L T cell transgenic mice. Weight of the Thymus (A), Spleen
(B) and Mesenteric Lymph node (C) of control, A238L and mutA238L T cell restricted transgenic mice. Each symbol represents an animal and black
and white circles and white squares correspond to 11 control, 17 A238L and 11 mutA238L transgenic mice, respectively. Haematoxylin eosin stained
sections of control mouse thymus (D) showing the typical cortex, with densely packed cells clearly differentiated from the medulla with less densely
packed cells, and transgenic A238L thymus (E), containing blood vessels (see arrows) and lacking structural organization. The infiltrate of the thymus
is accompanied by an increase in vascularisation (see arrows) (magnification 10X). At higher magnification, the transgenic thymus was seen to consist
of typical lymphoblasts and significantly more dense apoptotic nuclei than the control thymus (G) (Magnification 40X). Vascularisation of the T cell
restricted A238L transgenic thymus is also shown in the photograph (G), (note: blood vessel with its endothelial cell wall and shadows of red cells in
the lumen). The results are representative of at least 5 mice per founder and per genotype.
doi:10.1371/journal.pone.0034140.g002
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Figure 3. Phenotype of thymocytes from T cell restricted A238L transgenic mice. A) Surface phenotype of thymic cell suspensions of
control littermates (left), Tg A238L (middle) and Tg mut A238L mice (right). Cells were stained with antibodies specific for CD4-PE, CD8-APC and
CD69-FITC cell surface markers. Results are presented as CD4 versus CD8 (A) and the indicated CD4+CD8+ cells were then examined for CD69
expression (B, presented as CD4 versus CD69, and graphs E and F). The same cells were also stained with CD4-PE, CD8-APC, CD25-CyChr and CD44-
FITC, and the expression of CD25 and CD44 on CD4CD8 double positive cells was determined (C, presented as CD25 versus CD44). The analysis was
T Cell Lymphoma by Transgenic Expression of pA238L
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Clonality of the T Cells in the Tumours
TCR b-chain rearrangements were defined by Southern
blotting of EcoRV, HindIII, HpaI and PvuII digested DNA
samples from the thymuses of wild type control mice (Figure 5,
lane 9) and progeny mice of both A238L T cell restricted
transgenic founders (Figure 5, lanes 1 to 6). In addition, DNA
samples from two different thymic cell lines established in vitro,
each derived from different founder mice, were also digested with
the same enzymes (Figure 5, lanes 7 and 8). This Southern-blot
analysis uses a TCR b-chain constant region probe to define TCR
b-chain rearrangements [21].
Although a given restriction enzyme did not discriminate all
eight samples, comparison of the three enzyme digestions
(HindIII, HpaI and PvuII in Figure 5) established the unique
nature of the restriction enzyme profile, and thus the b-chain V-C
integration, of each sample. Thus these transformed cells must
have originated from the clonal expansion of a small number of
cells, and are therefore of mono or oligoclonal origin.
Metastasis of the Transgenic CD4+CD8+CD692
Transgenic Thymocyte to Peripheral Lymphoid Organs
and Non-lymphoid Tissues
The A238L transgenic mice presented enlarged (up to 15–20 X)
spleen and lymph nodes, often with a fibrous consistency, and
clearly infiltrated with lymphoblasts of the same
CD4+CD8+CD692, mostly CD25+ and CD3low, phenotype as in
the transgenic thymus (data not shown). In agreement with this,
there was a similar incorporation of BrdU in vivo in the
metastasised T cells of transgenic spleen and lymph nodes (data
not shown). In contrast, and as expected, in splenic T cells from
control and mutA238L transgenic mice, there was little or no
proliferation of either T or B cells. At the same time, however, the
B220 positive B cells present in A238L transgenic spleens did not
incorporate BrdU, consistent with the T cell restricted expression
of the transgene (results not shown).
As observed in the A238L transgenic thymus, the uncontrolled
proliferation of metastasised transgenic CD4+CD8+CD692 lym-
phoblasts completely disrupted the histological organization of
spleen and lymph nodes (Figure 6 shows only the mesenteric
lymph node). No organised B cell follicles or germinal centres were
observed. Instead, immunofluorescent staining of transgenic
spleen, revealed a homogeneous histology with the B cells
randomly scattered in a mass of T cells (photo not shown). The
metastasising transgenic CD4+CD8+CD692 lymphoblastic T cells
also colonized non-lymphoid tissue, such as liver, kidney and lungs
(data not shown). These organs were fibrous and usually presented
a paler colouration, particularly in the case of the kidney and liver.
Infiltrating lymphoblasts were of similar morphology to those
observed in the transgenic thymuses.
Expression of the transgene in these cellular infiltrates was
always confirmed by RT-PCR or western-blot.
The A238L Transgene Impairs Expression of NF-kB and
NFAT Downstream Genes
The expression profiles of the main CD4+CD8+CD692
population of thymic tumour cells present in the thymus of the
A238L transgenic mice were compared to the same cell
populations from wild type and mutA238L mice. For this, cDNA
was prepared from the purified population and hybridized onto
GeneChipH Mouse Genome 430A 2.0 Array (Affymetrix). This
also performed for splenic and lymph node cell suspensions and the same results were obtained (not shown). The reduced expression of CD3-APC
and TCRab-Alexa488 on T cell restricted A238L transgenic mouse thymocytes was demonstrated by staining with antibodies specific for CD3 and
TCRab (D, presented as CD3 versus TCRab, graphs E and F). The results are for groups of 5 mice per genotype and are representative of at least three
independent experiments.
doi:10.1371/journal.pone.0034140.g003
Figure 4. Demonstration of endothelial cells and VEGF synthesis in the thymus of the T cell restricted A238L transgenic mouse.
Cryostat sections of thymus of control littermates (left column), A238L Tg (middle column) and mutA238L Tg (right column) mice were stained with
antibodies specific for VEGF (upper row) (magnification 20X) and endothelial cells (CD31) (lower row) (magnification 40X). The results are
representative of at least 5 mice per founder and per genotype.
doi:10.1371/journal.pone.0034140.g004
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Chip is a single array representing approximately 14,000 well-
characterized mouse genes that can be used to explore biology and
disease processes, and in this case, to evaluate the impact of the T
cell selective expression of the A238L gene.
The analysis was performed by comparison of the data for the
purified transgenic thymic A238L T cells with cells of the similar
surface phenotype of the control mice, and considering that only
differences equal or greater than the absolute value of 3 are
relevant. The same rationale was used to compare the results for
the mutA238L and the control mice and for the A238L and the
mutA238L mice.
As can be seen on Table 1, the results of the comparison of the
A238L and the control and mutA238L are essentially the same in
respect of the number of affected genes as well as the category of
these genes.
When the results of the purified thymic T cells from the A238L
transgenic were compared to those obtained with wild type and
mutA238LT cells, a total of 1284 and 1345 genes, respectively,
displayed an absolute fold expression difference greater than 3
(Table 2). Interestingly, there was little difference comparing the
expression analysis of the mutA238L and wild type T cells.
The results of the gene chip analysis were then confirmed for
selected genes by semiquantitative PCR (Figure 7). The reduced
expression of the recombination activating gene 1 (Rag1) and
Rag2 genes, whose expression is crucial for the establishment of a
T cell receptor diversity is consistent with the existence of a limited
T cell repertoire, as detected by flow cytometry analysis (data not
shown), and also confirmed by the absence of expression of
TCRb-V8.2 (Figure 7A, 7B and 7C). The high expression of
CD25 observed in the A238L transgenic T cells was confirmed by
both the array and the PCR results (Figure 7D). Interestingly, the
A238L transgenic T cells did not express the forkhead box P3
(FoxP3) transcription factor, a specific marker of both natural and
adaptive/induced regulatory T cells [22], whereas there was no
such difference between the control and the mutA238L mice
(Figure 7E). Whether this difference is a direct or indirect
consequence of the expression of the transgene is not clear. There
is no doubt, however, of a profound impact of the A238L
transgene on the population of T cells so generated.
Three genes (Bcl3, Bcl2114, and Myc) were evaluated by PCR
due to their known impact on apoptosis and proliferation, two
features observed to be augmented in the A238L T cells, and
Figure 5. Southern-blot analysis of TCRb clonality of the thymic transgenic cells in the A238L T cell restricted transgenic mice. 30 mg
of DNA from the thymus of transgenic mice (lanes 1 to 6), of transgenic thymic in vitro established cell lines (lanes 7 and 8) and of wild type control
mice (lane 9) was digested with enzymes A) HindIII, B) PvuII, C) EcoRV and D) HpaI, as indicated on the top of the gels. Lanes 1 to 4 and 5 to 6 are of
progeny mice of Founders 1 and 2, respectively. The in vitro established cell lines, corresponding to lanes 7 and 8 were derived from Founders 2 and
1, respectively, and do not correspond to the mouse thymus DNA samples analyzed on the gel. Lane MW indicates the molecular weight marker used
and the corresponding values are indicated in the text box on its left.
doi:10.1371/journal.pone.0034140.g005
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Figure 6. Metastasis of thymocytes from T cell restricted A238L transgenic thymus. The figure shows sections of lymphoid organs stained
with Hematoxylin/Eosin (magnification 10 X). There is an exuberant infiltration ofmesenteric lymph nodes, with a corresponding loss of tissue
organization. (Not shown: There is also an infiltration of other tissues in areas around arteries and blood vessels, such as kidney, liver and lung and
morphology of the infiltrating lymphocytes is similar to that observed in the transgenic thymuses) The results are representative of at least 5 mice per
founder and per genotype.
doi:10.1371/journal.pone.0034140.g006
Table 1. Expression analysis of CD4+CD8+CD692 thymocytes reveals a distinctive pattern of some affected categories of genes for
the A238L transgenic mice.
Gene ontology Number of genes affected/category
A238L vs Wt A238L Vs mutA238L
cell cycle 87 88
cell division 59 59
chromosome, pericentric region 15 15
cyclin-dependent protein kinase regulator activity 12 12
cytokinesis 11
DNA binding 210
DNA replication 43 47
DNA replication initiation 8 9
DNA-dependent ATPase activity 10 11
DNA-directed DNA polymerase activity 10 12
kinetochore 9 212
mitosis 41 43
nuclease activity 22 21
nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process
12 13
nucleotidyltransferase activity 21 20
nucleus 458 464
purine nucleotide biosynthetic process 7 7
replication fork 7 7
ribonuclease H activity 7 6
RNA binding 78 84
single-stranded DNA binding 11 14
doi:10.1371/journal.pone.0034140.t001
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reflected by their increased expression as seen in the PCR
(Figure 7F, 7G and 7H).
Similarly, the PCR analysis of the A238L transgenic T cells
confirmed: (1) the exhuberant expression of the Proliferating Cell
Nuclear Antigen (PCNA) (Figure 7I), consistent with the increased
proliferation of the A238L transgenic thymocytes demonstrated by
incorporation of BrdU; (2) the decreased expression of 2 genes (IL-
2 and NFAT-1) controlled by the NFAT transcription factor
(Figure 7J and 7K) and (3) The reduced expression of the IL-2
inducible T cell Kinase gene (Itk), which is controlled by IL-2 and
thus the predicted result (Figure 7L).
Discussion
This work demonstrates that virus host evasion genes can be
used as probes to manipulate the genetic programme of
mammalian cells in vivo. Thus, T cell restricted transgenic
expression of a virus host modification gene (A238L of ASFV)
inhibiting transcription mediated by both p65 (NF-kB) and NFAT
has resulted in a transformation event at the CD4+CD8+ stage of
T cell development yielding an aggressive (mono-)oligoclonal,
angiogenic, metastasising and transplantable CD4+CD8+CD692
lymphoma. This pattern of expression of CD4 and CD8 DP has
been previously described for some human T cell acute
Table 2. Expression analysis of CD4+CD8+CD692 thymocytes reveals a distinctive pattern for the A238L transgenic mice.
x Mice/y mice Number of genes with fold expression ?Tg/Wt ?$3 P value
A238L/control 1284 0.000001,P,0.00036
A238L/mutA238L 1345 0.000001,P,0.000851
mutA238L/control 0 0.000199,P,0.000878
doi:10.1371/journal.pone.0034140.t002
Figure 7. Expression analysis of CD4+CD8+CD692 thymocytes demonstrates selective effect of the expression of the A238L
transgene in the A238L transgenic mice. Semi-quantitative PCR analysis of the cDNA prepared from the mRNA of the purified CD4+CD8+CD692
thymic cells of A238L and mutA238L transgenic and control mice shows that the A238L transgenic mice display a distinctive pattern of expression for
a group of selective genes which correlates to the phenotype of the mice. b-Globin was used as the housekeeping gene. The results presented
correspond to a pool of 5 mice per genotype.
doi:10.1371/journal.pone.0034140.g007
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lymphoblastic leukaemias [23] and in mice with T cell restricted
transgene expression of c-myc [24].
The viral gene selected for this study was the A238L of ASFV, a
dual inhibitor of NF-kB and NFAT mediated transcription [9–12].
Although in the course of a natural infection with ASFV the cells
that are infected are porcine macrophages and not mouse T cells,
A238L has been shown to maintain its activity as an inhibitor of
NFAT and p65 when the viral protein is expressed in monkey
fibroblasts (Vero cells), in human T cells (Jurkat cells) and in mouse
macrophages (Raw 264.7 cells) [10,13,14,25]. This non-specific
species and tissue impact predicts that the A238L would function
at the level of murine T cells, as the transgenic tumour phenotype
confirms.
A key question is whether the neoplastic transformation of the
A238L transgenic mice results from expression of the transgene or
is simply the consequence of its integration site. The available
evidence strongly argues in favour of the first alternative. Thus,
integration of the A238L transgene into the genome occurs
randomly and yet progeny of two distinct founder mice presented
the same phenotype. Second, sequencing of the A238L transgene
in both founder mice demonstrated the presence of the entire un-
mutated sequence. Third, the fact that the only cells whose
development is abrogated and disrupted are T cells, is strong
evidence that the effect observed is the direct result of selective
A238L transgene expression. Fourth, direct proof of transgene
expression was demonstrated in transgenic thymus at mRNA (RT-
PCR) and protein (fluorescent antibody) levels.
Importantly, a similar transgenic mouse was created, but
expressing a point mutated version of the A238L which results
in its inability to interact with CanPase, so that this transgene
solely inhibits the activation of p65. As described in the Results,
these transgenic mice were indistinguishable from the wild type
animals. We may therefore conclude that inhibition of activation
of NFAT is essential for the observed neoplastic transformation in
the A238L transgenic mice, and that inhibition of activation of p65
may not be a key factor in the mechanism of the observed
neoplastic transformation.
The analysis of the pattern of expression of these
CD4+CD8+CD692 thymocytes, assessed by array analysis and
confirmed by PCR, revealed a series of coherent and relevant
information that is consistent with the phenotype presented by the
A238L transgenic mice and with the outcome anticipated due to
the expression of A238L; that is, inhibition of activation of p65 and
inhibition of CanPase with consequent lack of activation of the
NFAT proteins. Thus, the array and PCR analysis demonstrated
increased expression of the Bcl3, Bcl2l14, Myc and PCNA and
decreased expression of NFAT1, IL-2 and Itk.
The Bcl3 gene is a proto-oncogene candidate [26], currently
considered to be a molecular marker of anaplastic large cell
lymphoma [27] and over-expression of the Bcl2l14 gene has been
shown to induce apoptosis in cells [28,29]. The induction of
apoptosis in the A238L transgenic thymus is consistent with the
increased expression of Bcl2l14 revealed by the chip and
confirmation by PCR analysis. Similarly, Myc has been associated
to several forms of cancer and is known to drive cell growth and
cell proliferation, up-regulating cyclins [30]. The Proliferating Cell
Nuclear Antigen (PCNA) gene codes for a protein that acts as a
processivity factor for DNA polymerase d in eukaryotic cells [31]
and its exuberant expression in the A238L transgenic mice
confirms the PI and BrdU flow cytometry analysis. As expected,
the expression of two genes whose expression is known to be highly
controlled by the NFAT family of transcription factors, IL-2 and
NFAT1 was dramatically decreased in the A238L transgenic mice.
Finally, the IL2-inducible T cell kinase (Itk) gene, codes for an
intracellular tyrosine kinase expressed in T cells which plays a
major role in T cell proliferation and differentiation, regulating
signalling from the T cell receptor (reviewed in [32]). Its expression
is induced by IL-2 itself, so it is therefore not surprising that the
A238L transgenic tumorigenic T cells displayed a dramatic
reduction in its expression, when compared to control and
mutA238L transgenic mice. Significantly, the expression analysis
of the mutated A238L transgenic mouse thymocytes was
comparable to normal thymocytes.
These features, together with the demonstration of (mono-)
oligoclonality, suggest a transgene-NFAT-dependent transforma-
tion yielding a lymphoma with a phenotype reminiscent of some
acute lymphoblastic lymphomas. The detailed molecular mecha-
nism of the transgene induced transformation, like many
neoplastic transformations, is still not clear, and the multiple
activities of the A238L transgene (see introduction) certainly
provide a variety of possibilities for future exploration in the
transgenic mouse in the future.
Virus strategies for manipulating transcription provide tools for
understanding mechanisms of transcription and may complement
the analysis of knock-out mice. Extensive work has been done to
elucidate how some families of transcription factors impact on T
lymphocyte development and function. Several knock-out mice,
both with T cell selective and whole body expression, have been
constructed for different NFAT and NF-kB proteins, as well as
mice that over express IkB proteins. However, the resulting
phenotypes are not always predictable from previous data because
it is believed that the outcome depends on the cellular context, that
is the cell from which the transcription factor or inhibitor was
knocked-out from, or in which the inhibitor protein was over-
expressed. Moreover, knocking-out a given NF-kB protein may
not be necessarily equivalent to over expressing its respective
inhibitor.
There are, however, some correlations between the phenotype
of our transgenic mouse and the previously described NF-kB and
calcineurin deficient mice. For example, it is known that NFAT4
controls the transition of developing thymocytes from the DP
CD4+CD8+ immature stage to the CD4+ or CD8+ single positive
stage [33], and a tumour suppressor function has also been
indicated for NFAT4 in the genesis of T cell lymphomas induced
by insertion of the retrovirus SL3-3 [34]. Particularly relevant in
this study, NFAT4 KO mice developed tumours with immature
CD4+CD8+ DP thymocytes. Also, deletion of calcineurin Ab
resulted in reduced numbers of SP thymocytes, which demon-
strates the involvement of the enzyme in positive selection [35].
The fact that the transformed lymphoblasts of the A238L
transgenic mice do not progress from the DP to the SP stages of
thymocyte development may therefore correlate with the effect of
knocking out NFAT4. Moreover, the A238L transgenic mice also
displayed massive lymphadenopaty and splenomegaly, as it has
been described for double KO for NFAT1 and NFAT4 mice [36].
On the other hand, mice deficient in individual NF-kB subunits
show no intrinsic defect in the establishment of normal population
in the T cell lineage [37–42]. Again, and interestingly, our
mutA238L T cell restricted transgenic mice behaved like this, as
they exhibited normal population of T cells and were indistin-
guishable from the control animals in all of the parameters that we
evaluated.
The IkB domain of the A238L molecule is expected to inhibit
NF-kB activation. The possible importance of NF-kB in positive
and negative selection of T cells is indicated by over expressing the
IkBa inhibitor in T cells, which results in a reduction of the
proportion of mature TCRhigh of the ab-lineage coupled with an
unusually high proportion of DP thymocytes [43]. Taking all of
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the above into consideration, the phenotype exhibited by our
A238L T cell restricted transgenic mice could be the result of
inactivating NFAT without necessarily inactivating the NF-kB
family of transcription factors, this in turn causing a transforma-
tion event at the DN stage, perhaps prior to the process of positive
selection as evidenced by the absence of expression of CD69 in the
thymus. The absence of CD69 expression in the lymphoma
suggests that the transformation event took place prior to positive
selection. It must be admitted, however, that a possible
participation of NF-kB can not be entirely ruled out.
In conclusion, virus host evasion genes may function as tools for
genetic manipulation at the level of the whole animal. Elucidation
of the molecular events associated with the development of this
virus host evasion molecule induced metastasising, angiogenic
tumour may clarify some mechanisms of tumorigenesis in general,
and in the development of T cell acute lymphoblastic leukaemia in
particular. Finally, the phenotype of the T cell restricted A238L
transgenic mouse would have been predicted from the recent
suggestion for targeting calcineurin activation as a therapeutic
intervention in acute T cell lymphoblastic leukaemia [44].
Materials and Methods
Mice
FVB/N mice were produced and kept at the IGC (Oeiras,
Portugal). The B6xCBA mutA238L founder mice were produced
at the Transgenic Facility of Umea˚ University, Sweden and kept at
the IGC (Oeiras, Portugal).
Ethics Statement
All the animal work was conducted in compliance with the
Portuguese and European laws (Portaria 1005/92 and Directive
86/609/EEC, respectively), and following the FELASA recom-
mendations. All animal experiments were performed at the IGC
animal house, which is licensed by the portuguese national entity,
Direcc¸a˜o Geral de Veterina´ria (Laboratory permission 520/000/
000/2518/99). All efforts were made to minimize animal suffering.
Gene Amplification and Plasmid Construction
The A238L gene was amplified by PCR from DNA of the non-
pathogenic ASFV Ba71v strain using Pfu DNA polymerase,
dNTPs 200 mM, primers 1 mM, MgSO4 3 mM, 95u-29, 30X (95u-
19, 44u-19, 74u-29), 74u-59, and the primers: Up, 59-CTAGAATT-
CATGGAACACATGTTTCCA-39, Low, 59-CTACTCGAGT-
TACTTTTCATACTTGTT-39. A mutated version of A238L,
(mutA238L) with mutations introduced in the CanPase binding
motif of A238L, yields a protein which no longer interacts with
CanPase, and is, thus, incapable of inhibition of CanPase,was
provided by Dr Linda Dixon. The mutations were introduced in
residues 200 to 213 [12], leaving the ability of mutA238L to inhibit
p65 intact.
The gene was cloned as a 59EcoRI-39XhoI fragment into the
SVA(-) vector, which confers T cell specific expression, with an
upstream Influenza haemaglutinin peptide (HA) tag. The
expression cassette was released from the bacterial backbone
(pBluescript SK-) by digestion with SfiI and microinjected into
FVB/N fertilized eggs, which were implanted into pseudo-
pregnant foster females. Founder mice for the A238L transgenic
were crossed with wild type FVB/N mice to obtain hemizygous
mice. Subsequent crossing of hemizygous mice, yielded homozy-
gous animals. The same procedure was used for the founders of
the mutA238L B6xCBA founder mice and all the analysis were
performed in the FVB/N strain, easily identifiable by the coat
white colour. Control animals were littermates without the
transgene.
Sequencing
Sequencing was done using primers derived from the sequence
of the SVA(-) plasmid, specifically, upstream and downstream of
the EcoRI and XhoI sites, respectively: Up, 59-
TTCTTCCAAAGGTAAGCATAAGAGTCAAAG-39 and Low,
59-GTTTCTATCTTTTTTAATTAGAGGAAGGGG-39. The
kit used was BigDye terminator v1.1, Part Nu 4336776, Applied
Biosystems and the cycling conditions were 96u-19 and 25X (96u-
100, 50u-50, 60u-49). The PCR products were analysed on a 377
DNA Sequencer and 3130xl Genetic Analyser, Applied Biosys-
tems.
Construction of the Transgenic Mice
In order to achieve selective expression of the transgene in T
cells, the A238L virus gene was sub-cloned into a plasmid
containing a modified human CD2 promoter which ensures
expression of the transgene at the DN stage of T cell development,
with minimal expression in B cell lymphocytes and ensures that
expression is independent of the integration site and proportional
to the number of integrated copies of the transgene [45].
Four A238L transgenic mice, two males and two females, were
obtained from a litter of 7 mice after injection of fertilized eggs
with an expression cassette containing the A238L transgene and
an upstream HA immuno-tag. Upon Southern blot analysis, three
of the four mice presented a transgenic DNA fragment of the
expected size. One of the two females exhibited a smaller than
expected transgene and was discarded, and the second female
founder mouse died. The remaining two male founders were
crossed with FVB/N females and the F1 mice were bred to yield
F2 mice.
For the construction of the mutA238L transgenic mice, two
male and two female transgenic mice, were obtained from a litter
of 7 mice after injection of fertilized eggs with the expression
cassette of the SVA plasmid containing the mutA238L transgene
and an upstream HA immuno-tag. Upon Southern blot analysis,
all the founder mice presented a transgenic DNA fragment of the
expected size, and were crossed with wild type FVB/N mice. The
resulting F1 mice were further crossed to yield the F2 generation
and only the mice that were of the FVB/N phenotype (white
colour) were kept and analysed. The sequence of the transgene
integrated into the DNA of the 4 transgenic founder mice was
determined, after PCR amplification with Pfu, and was complete
and identical to the published NCBI A238L sequence, apart from
the point mutations introduced into the CanPase binding sequence
[12].
Mouse Genotyping by Southern Blot and PCR and
Sequencing of the Transgene
Samples of genomic mouse DNA (10 mg) isolated from tail
biopsies by standard methods were digested with EcoRI and XhoI
and electrophoresed on a 0.8% agarose gel. Treatment of the gel,
transfer to the membrane Hybond-N+ and hybridization were
done according to the instructions of Hybond-N+ (Amersham,
U.K.). The 718 bp A238L probe was labelled with a32P-dCTP
using the Random Primers DNA Labelling System, Gibco,
according to the manufacturer’s instructions. Unincorporated
probe was removed using G-50 Sephadex Quick Spin Columns,
Gibco. The results were also assessed by PCR, as described above.
Mice were then routinely genotyped by PCR using DNA from
tail biopsies obtained at the time of weaning (3 weeks old). Tails
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were digested overnight with Proteinase K (100 mg/ml) at 56uC
and then DNA was precipitated with isopropanol (0.7 volumes) at
room temperature.
The primers described for sequencing the DNA plasmid
construct were also used to sequence the transgene in the genomic
DNA of the 2 founder transgenic mice of each genotype, after
amplification with Pfu DNA Polymerase as previously described.
Determination of the Number of Copies of the Transgene
The number of copies of the transgene was evaluated by the
Real Time PCR technique using LightCycler FastStart DNA
Master SYBR Green I (Roche).
The amount of amplified A238L transgene (primers Up, 59-
ATGGAACACATGTTTCCAGAAAGG-39, Low, 59-
TTACTTTCCATACTTGTTCAGTTT-39) was normalized
against the amount of amplified mouse b-Globin (primers Up,
59-CCAATCTGCTCACACAGGATAGAG-39, Low, 59-
CCTTGAGGCTGTCCAAGTGATTCA-39). Conditions were
MgCl2 4 mM, primers 200 nM. Program for A238L: pre-
incubation 95u-109, amplification 45X (95u-109, 70u-50, 72u-290),
Melting Curve Analysis (65u-150); program for b-Globin: pre-
incubation 95u-109, amplification 45X (95u-109, 70u-50, 72u-200),
Melting Curve Analysis (65u-150). Analysis was performed with the
Roche supplied software and calculations on the amount of
amplified product were based on the determination of the second
derivative maximum and on an arithmetic adjustment of the
baseline.
Demonstration of Transgene Expression by RT-PCR
Total RNA was extracted from tissue homogenates of thymus,
spleen and liver from transgenic and control littermates using
Trizol Reagent (Sigma). Samples of RNA were digested with
DNaseI (Invitrogen) and cDNA synthesis was performed with
MMLV-Reverse Transcriptase (Invitrogen), according to the
manufacturer’s instructions. Detection of the A238L gene in the
cDNA by PCR was performed as above, but using Taq DNA
Polymerase, MgCl2 2 mM and performing the extension at 72uC.
As a qualitative and semi-quantitative control, mouse tubulin was
amplified using Taq DNA Polymerase with dNTPs 200 mM,
primers 1 mM, 1.5 mM and primers were: Up, 59-ATGCGT-
GAGTGCATCTCCATCCACGT-39 and Low, 59-TTAG-
TATTCCTCTCCTTCTTCCTCAC-39 and cycling conditions
were 94u-59, 30X (94u-19, 55-19, 72u-29), 72u-109.
Flow Cytometry Analysis of Lymphocyte Surface Proteins
Cell suspensions were incubated with titrated concentrations of
the antibodies used, washed in PBS containing 2% FCS and
0.02% sodium azide and subsequently analyzed on a FACScali-
bur. All rat monoclonal antibodies (CD3-APC, CD4-PE, CD8-
APC, CD25-PE, CD25-biotin, CD44-FITC, CD69-FITC and
TCRab-Alexa488, Streptavidin-CyChrome) were purchased from
BD Pharmingen (San Diego, CA). Except for the four colour
stainings, Propidium Iodide (PI) was always used to exclude dead
cells from the analysis that was performed using the FlowJo
software (Tree Star, Inc.).
Analysis of T Cell Clonality by Southern-blot
Thymus DNA samples were prepared as described for tail
DNA. Thymic cell lines were lysed in White Cell Lysis Buffer
(WCLB, 3 ml/506106 cells) (10 mM Tris- HC1 (pH 7.6), 10 mM
EDTA (pH 8.0), 50 mM NaCl) and incubated overnight at 56uC
with 0.165% (v/v) and Proteinase K (165 mg/ml), and extracted
twice with phenol-chloroform-isoamyl alcohol and once with
chloroform-isoamyl alcohol. After adding NaCl to 0.1 M the DNA
was precipitated with isopropanol (0.6 vol).
30 mg of thymus DNA of wild type and transgenic mice were
digested O/N with EcoRV, HindIII, HpaI and PvuII and
separated on a 0.7% agarose gel. Treatment of the gel, transfer
to the membrane Hybond-N+ and hybridization were done
according to the instructions of Hybond-N+ (Amersham, U.K.).
The 454 bp TCR b constant region probe [46] (provided by
Dimitris Kioussis, National Institute for Medical Research, U.K.)
was labelled with a32P-dCTP using the Random Primers DNA
Labelling System, Gibco, according to the manufacturer’s
instructions. Unincorporated probe was removed using G-50
Sephadex Quick Spin Columns, (Gibco).
Splenic B Cell Purification with MACS LS Columns and
Streptavidin Microbeads
Splenic cell suspensions were depleted of erythrocytes by
resuspending in ammonium chloride 0.155 M, potassium hydro-
genocarbonate 0.01 M, pH 7.2. After 3 washes in PBS-2% FCS,
the cells were labelled with anti-B220-biotin (BD Pharmingen, San
Diego, CA), incubated with Streptavidin Microbeads and then
purified with MACS LS Columns (Miltenyi Biotec, CA). At least
95% of the recovered cells were B cells.
Histology and Immunofluorescence
Tissues were fixed in Bouin’s solution (Sigma), embedded in
paraffin and stained with hematoxylin and eosin.
For immunofluorescence, tissue samples were frozen in tissue-
tek O.C.T. compound (Sakura Finetechnical), and 8 mm cryostat
sections were fixed (absolute ethanol, 59-room temp, followed by
acetone, 59-room temp) and air dried. Rat anti-mouse CD-31
(mAb) and Goat anti-rat (IgG and IgM) Alexa 568 were purchased
from BD Pharmingen (San Diego, CA) and from Molecular
Probes, respectively. Biotinylated anti-murine VEGF (polyclonal
Ab) and Streptavidin-Texas Red were purchased from Peprotech
EC and SouthernBiotech, respectively. AnnexinV-Alexa 567 was
purchased from Invitrogen, and FITC-Rat monoclonal anti-HA
was purchased from Roche.
Expression Profiles of CD4+CD8+CD692 Purified
Thymocytes
Thymic cell suspensions of Wt, mutA238L and A238L mice
(pools of 5 mice) were incubated with titrated concentrations of the
antibodies used, washed in PBS containing 2% FCS and
subsequently analyzed and purified on a FACSAria cytometer
(BD), gating on the thymic cell population that was
CD4+CD8+CD692. All rat monoclonal antibodies (CD4-PE,
CD8-APC, CD69-FITC) were purchased from BD Pharmingen
(San Diego, CA). The purity of the population was verified by flow
cytometry in a FACScalibur cytometer (BD) and was always
greater than 98%.
Total RNA from the purified cell population was extracted with
Mini RNeasy Kit (QIAGEN), digested with DNaseI (Invitrogen)
and cDNA synthesis was performed with the 3`IVT Express kit
(Affymetrix), according to the manufacturer’s instructions. The
cRNA was hybridized into GeneChipH Mouse Genome 430A 2.0
Array (Affymetrix), according to the manufacturer’s instructions.
This analysis was done once (results are available in the GEO
database as follows: GSE34048-Transgenic Expression of A238L,
a Virus Host Modification Protein in mouse T cells; GSM840978-
mouse CD4+CD8+CD692 thymocytes purified Wt; GSM840979-
mouse CD4+CD8+CD692 thymocytes purified A238L;
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GSM840980-mouse CD4+CD8+CD692 thymocytes purified
mutA238L).
The results for the A238L mice results were normalized against
the Wt and the mutA238L and only values with more than a 3 fold
difference were considered. As a comparative control study, the
mutA238L mice results were also normalized against the Wt mice.
The microarray results were confirmed by conventional semi-
quantitative PCR using primers designed between adjacent exons
to discriminate cDNA from contaminating undigested genomic
DNA that might be present and using b-globin as the control
housekeeping gene. Amplification to detect the selected genes in
the cDNA was performed using Taq DNA Polymerase with
dNTPs 200 mM, primers 1 mM, MgCl2 2 mM and performing the
extension at 72uC. The PCR amplification program consisted of
20–25 cycles, to ensure that saturation was not reached and that
the differences detected in the microarray would be demonstrated
in the visualization of the amplified fragments with ethidium
bromide in a 0.8% standard agarose gel.
Primers and size of amplicon for the selected genes were: b-
globin PCR product 500 bp Up 59-ccaatctgctcacacaggatagag-39,
Low 59-ccttgaggctgtccaagtgattca-39; FoxP3-PCR product 331 bp,
Up 59 ctgcctacagtgcccctagtcat 39, Low 59 ctgtctttcctgggtgtacccga
39; IL2-PCR product 400 bp, Up 59 atcctgtgtc acattgacac 39, Low
59 gcactcaaatgtgttgtcag 39; Rag1-PCR product 400 bp, Up 59
ccgtctaccctgagcttcagtt 39, Low 59 ctttgggttttagcgtccacgg 39; Rag2-
PCR product 382 bp, Up 59 tccctgcagatggtaacagt 39, Low 59
agtctttctctgtgcaacgg 39; Bcl3-PCR product 557 bp, Up 59
tgatgcccatttactctacccc 39, Low 59 cataattgcgaacctccaggtc 39;
Bcl2l14-PCR product 316 bp, Up 59 tttgttggattccaaagtggcttg 39,
Low 59 aacaggtctgtgatggtcttga 39; NFAT1-PCR product 375 bp,
Up 59 ctccacggctacatggagaac 39, Low 59 agcactcgatggggttggacg 39;
ItK-PCR product 443 bp, Up 59cgttgaagggctccattgaac 39, Low 59
cattcttggatgggtcgtagg 39; Tcrbeta V8.2-PCR product 408 bp, Up
59GACATACAAATGCACCTATGCG 39, Low 59
TTAGGCCTCTTCCAGAAGTAGA 39; Myc-PCR product
370 bp, Up 59aactatgacctcgactacgact 39, Low 59 tccacatacagtcctg-
gatgat 39; CD25- PCR product 329 bp, Up 59 cccatgacaaatcga-
gaaagca 39, Low 59cagaaatcggtggtgttctctt 39; proliferating cell
nuclear antigen (PCNA)- PCR product 320 bp, Up 59 acgtctcctt
ggtacagctt 39, Low 59 gtctcggcatatacgtgcaa 39.
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